Corporate Headquarters:
1 Scotts Road, Shaw Centre #20-08, Singapore 228208.
About Us
Our Network
News & Events
Copyright © 2025 Tamarind Health. All rights reserved.
Singapore, 15 October 2025 – Tamarind Health marks the next phase in its growth as Asia’s leading integrated oncology-focused healthcare platform, following the completion of its acquisition of TalkMED in September 2025. A doctor-led platform built on the principle of putting patients first, Tamarind Health brings together leading medical practices across the region under a single umbrella.
The platform reflects the shared vision of renowned specialists, beginning with the founding doctors of OncoCare Singapore, Dr Miah Hiang Tay and Dr Peter Ang. Their practice has set the benchmark for quality of care and serves as the operating model for Tamarind Health’s regional expansion. The recent addition of TalkMED, led by Dr Peng Tiam Ang, further reinforces the Group’s commitment to raising the standards of cancer care for patients across Asia.
Tamarind Health’s network now spans 36 outpatient and hospital-based centres across Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China. Besides OncoCare and TalkMED, this includes Solis, Luma, Novena Heart Centre, Tamarind Specialists, and Can-Care. Together, the Group supports more than 180,000 patient visits each year with a combined team of over 500 doctors and staff.
Tamarind Health was formed to address a critical gap in the region’s healthcare. While cancer cases are rising sharply across Asia, patient care remains fragmented. The Tamarind Health platform brings together the region’s renowned specialists and their practices across the full spectrum of oncology care, integrating their clinical expertise on a scale never seen before in Asia. The goal is to create a new and differentiated model for cancer care – one that combines advanced diagnostics, innovative therapies, complementary surgeries and treatment, and access to clinical trials with personalised survivorship and well-being support to ensure patients are cared for both medically and emotionally.
A key differentiator of Tamarind Health is that the platform enables collaboration and knowledge-sharing among doctors, creating more opportunities for sub-specialisation and professional development. By tapping into a broader network of expertise, doctors are better able to form multidisciplinary teams that generate ideas, solve problems, and deliver care in more innovative and integrated ways. Patients are then able to access sub-specialised care in a world where treatments are becoming increasingly personalised.
Dr Miah Hiang Tay, Co-Founder of OncoCare Singapore and Board member of Tamarind Health, said: “From the start, our goal has been to keep making progress in the fight against cancer – step by step, patient by patient. Tamarind Health now gives us the platform to do that together, on a much larger scale. By coming together, we can go beyond what any single practice can achieve – accelerating research, developing innovative treatments, and pushing the boundaries of what’s possible in cancer care.”
Dr Peter Ang, Co-Founder of OncoCare Singapore and Board member of Tamarind Health, said: “With the field of oncology becoming increasingly specialised, collaboration across disciplines has become essential to delivering high-quality care. At Tamarind Health, the development of sub-specialty groups under one platform creates the right environment for clinical collaboration, sharper decision-making, and continuous learning. This allows us to care for more patients, achieve better outcomes, and stay true to the values that brought each of us into this profession.”
Dr Peng Tiam Ang, Founder of TalkMED and Board member of Tamarind Health, said: “Our patients and their families come to us for understanding of their disease, confidence, and care they can trust. Tamarind Health enables us to extend that promise to more people in more places – with consistent standards, a shared commitment to excellence, and the backing of a regional team of specialists.”
Dr Miah Hiang Tay, Dr Peter Ang, and Dr Peng Tiam Ang continue to hold equity in the Group and serve on the Board, ensuring that patient care and clinical standards stay firmly at the heart of the Group’s decision-making.
-END-
About Tamarind Health
Tamarind Health is Asia’s leading integrated oncology-focused group, uniting renowned practices across the region to elevate care and improve patient outcomes. Headquartered in Singapore, the doctor-led platform brings together specialists across the full spectrum of oncology, from diagnostics and treatment to survivorship and well-being.
Our journey began with the acquisition of OncoCare Singapore and Novena Heart Centre, laying the foundation of our oncology and cardiac expertise. This foundation was broadened with Solis, Luma, OncoCare Philippines, and Can-Care, expanding our focus into breast care and post-care services. The network subsequently grew to include OncoCare Malaysia, OncoCare Hong Kong, and Tamarind Specialists, strengthening our regional presence. Most recently, the addition of TalkMED strengthened our presence in Singapore and extended our reach into Vietnam and Mainland China, further enhancing our scale and depth of expertise across Asia.
With the purpose of setting new standards in healthcare for better results, Tamarind Health is shaping the future of oncology and related services across six markets: Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China.
We Believe in Better.
For more information, visit: https://tamarindhealth.com
For further information, please contact:
Tamarind Health
Joanne Liu, VP, Group Brand & Communications
joanne.liu@tamarindhealth.com
Brunswick Group
tamarindhealth@brunswickgroup.com
Shareholders of TalkMed Group Limited have overwhelmingly approved Tamarind Health’s privatization scheme. At the meeting held on 15 July 2025, 99.9% of the represented shares voted in favor.
Under the approved scheme, TalkMed will be delisted from the Singapore Exchange (effective 15 September 2025) and integrated into Tamarind Health’s oncology network.
The transaction structure includes service-agreements for founder doctors in their new roles, reinvestment of part of the consideration into Tamarind shares, and safeguards to ensure fairness to independent shareholders under Singapore’s takeover code.
This marks a significant step in Tamarind Health’s vision to unify oncology practices across the region and deepen integrated cancer care capabilities.
Read the full article on Business Times
The Competition and Consumer Commission of Singapore (CCCS) has approved Tamarind Health’s proposed acquisition of TalkMed Group Limited. Following a detailed review, CCCS concluded that the transaction will not result in a substantial lessening of competition within Singapore’s private oncology sector.
This marks an important milestone in Tamarind Health’s mission to build Asia’s leading doctor-led oncology network, uniting renowned specialists and practices across the region to advance cancer care and patient outcomes.
The acquisition strengthens Tamarind Health’s integrated oncology ecosystem, enhancing collaboration between its practices in Singapore, Malaysia, Hong Kong, and the Philippines, and expanding access to multidisciplinary expertise, advanced treatments, and compassionate care.
Read the full article on The Business Times
In December 2024, Tamarind Health, supported by 65 Equity Partners, announced a S$0.456 per share offer to privatize TalkMed Group, with plans to delist the company from public trading.
This move is designed to strengthen oncology care by unifying resources, fostering deeper specialization among physicians, and improving patient access to integrated cancer treatment services.
Under the proposed structure, 65 Equity Partners would take an ~18.3% voting stake in Tamarind Health, while doctor shareholders would hold ~31.3%.
TalkMed’s founders (Ang Peng Tiam, Khoo Kei Siong, Lim Hong Liang, Teo Cheng Peng) already hold an 83.06% combined stake and have given irrevocable undertakings to sell their shares.
Tamarind Health’s network now includes oncology and related practices across Singapore, Malaysia, Hong Kong, the Philippines, and more — and this acquisition fits its vision to build a pan-Asian oncology ecosystem.
Read the full article on TechNode
On 23 December 2024, TW Troy Limited — a wholly-owned subsidiary of Tamarind Health — entered into a binding agreement to acquire TalkMed Group, a company listed on the Singapore Exchange.
This strategic move aligns with Tamarind Health’s vision of building a pan-Asian, doctor-led oncology platform by bringing TalkMed into its integrated network.
Further details are available in the SGX Joint Announcement & Press Release issued concurrently.
Read the full release on Templewater
(29 November 2024, Singapore) Templewater is pleased to announce the launch of Tamarind Health Limited (“Tamarind Health”), a healthcare group bringing together leading oncology-specialist practices and assets across Asia.
The group currently integrates — among others — OncoCare, Solis / Luma, Can-Care, Novena Heart Centre in Singapore; Icon Cancer Centre in Hong Kong; and oncology practices in Malaysia and the Philippines.
The name “Tamarind Health” embodies a vision of holistic care rooted in strength and continuity. The tamarind tree is widely valued in Asia not only for its health and medicinal properties but also its enduring nature.
Tamarind Health evolved from a partnership (beginning December 2023) among Templewater, OncoCare, and Novena Heart Centre. In November 2024, TW Pengu Holdings Limited was renamed Tamarind Health Limited.
Read the full release on Templewater
2 October 2024, Hong Kong — Templewater is pleased to announce that its portfolio company TW Pengu Holdings Limited (TWPHL) has acquired ICON Group’s oncology assets in Hong Kong.
This acquisition supports TWPHL’s strategy to consolidate and expand oncology services across Asia, following prior expansions in Singapore, Malaysia, and the Philippines.
By integrating ICON’s Hong Kong operations into its portfolio, Templewater aims to deliver stronger synergies, broaden access to cancer care, and further its mission of advancing high-quality, patient-centric oncology across the region.
Read the full release on Templewater
(5 September 2024, Kota Damansara, Malaysia) — OncoCare Malaysia and Thomson Hospitals Sdn. Bhd. (“THSB”) have formalized their collaboration through an exclusive Service Provider Agreement to deliver oncology services at Thomson Hospital Kota Damansara (“THKD”).
Under this agreement, OncoCare Malaysia will provide comprehensive, patient-centred oncology treatments following a tumour site-specific approach aligned with oncologist specialities. The services will include clinical trials to expand access to advanced therapies, as well as alternative treatments designed to enhance patient outcomes and quality of life.
The partnership is a key milestone in OncoCare’s regional expansion. It builds on existing capabilities in Singapore and thereby extends its reach into Malaysia, harnessing combined clinical expertise, operational strength, and innovation to raise standards in cancer care across the region.
Read the full announcement on Templewater
(10 May 2024, Singapore) Templewater is pleased to announce that its portfolio company, TW Pengu Holdings Limited (TWPHL), has completed acquisitions of Singapore Breast Surgery Center (SBSC), Central Luzon Integrated Oncology Centre (CLIOC), and Can-Care from TE Asia Healthcare.
These acquisitions further strengthen and extend TWPHL’s capabilities across the oncology care spectrum:
SBSC (Solis / Luma brands) offers integrated breast cancer care in Singapore, covering screening, diagnostics, surgery, and imaging.
CLIOC (Philippines) provides tomotherapy and chemotherapy services, as well as related diagnostic and treatment support.
Can-Care operates post-cancer care retail and distribution, with outlets in Singapore and Malaysia.
These moves build on TWPHL’s foundation, which began with acquisitions of OncoCare and Novena Heart Centre, with the aim of creating a premier pan-Asian oncology group.
Read the full announcement on Templewater
(26 February 2024, Singapore) — OncoCare Medical (“OncoCare”), a portfolio company of Templewater, has entered into a Letter of Intent (LOI) with Thomson Hospitals Sdn. Bhd. (THSB) to negotiate exclusively on establishing oncology services in Kuala Lumpur, Malaysia.
This move marks a key step in OncoCare’s regional expansion strategy, leveraging its established presence in Singapore to extend cancer care offerings to Malaysia.
THSB, a subsidiary of TMC Life Sciences Berhad and operator of hospital facilities that serve the greater Kuala Lumpur region, brings a strong local infrastructure and reputation.
Through this collaboration, OncoCare aims to bring its multidisciplinary, patient-centric oncology services to more patients in Malaysia with reliable access and high standards of care.
Read the full announcement on Templewater
(15 December 2023, Singapore) — Templewater is pleased to announce that it has successfully completed the acquisition of OncoCare Medical and Novena Heart Centre (NHC).
OncoCare, founded in 2007, is a leading private medical oncology group in Singapore. It currently operates seven clinics across key hospitals and medical centres.
NHC, also established in 2007, is one of Singapore’s largest multi-disciplinary cardiology groups, operating three state-of-the-art cardiology clinics across the city.
This acquisition underscores Templewater’s commitment to the healthcare sector in Southeast Asia. It positions the group to deliver high-quality oncology and cardiovascular care through unified operations, shared expertise, and integrated services.
Read the full announcement on Templewater
(24 October 2023, Singapore) — Templewater is pleased to announce that it has signed definitive agreements to acquire OncoCare Medical (“OncoCare”) and Novena Heart Centre (“NHC”), two prominent private specialty clinic groups in Singapore.
OncoCare, founded in 2007, operates a network of seven clinics in Singapore and brings together 13 specialist oncologists across tumour-site disciplines.
NHC, also founded in 2007, maintains three clinics and comprises a team of five cardiologists and a visiting cardiothoracic surgeon, offering both inpatient and outpatient cardiology care.
Cliff Zhang, Founding Partner and CEO of Templewater, remarked that this marks Templewater’s first investment in the healthcare sector and underscores its commitment to deploying capital into high-quality healthcare assets across Asia.
Templewater intends to support the OncoCare and NHC medical teams with resources, capital, and operational capabilities to expand their practices regionally.
Read the full announcement on Templewater
Corporate Headquarters:
1 Scotts Road, Shaw Centre #20-08, Singapore 228208.
Corporate Headquarters:
1 Scotts Road, Shaw Centre #20-08, Singapore 228208.
Eng Seng brings over 20 years of experience spanning healthcare, private equity, and financial services across Asia. As Group Chief Executive Officer at Tamarind Health, he drives the group’s strategic growth initiatives, partnerships, and cross-border expansion, combining his deep expertise in investment and operations.
He has led healthcare investment consulting projects across Hong Kong, Singapore, the Philippines, and Malaysia, managing transactions ranging from US$30 million to over US$500 million since the firm’s inception.
Previously, Eng Seng served in senior roles at TE Asia Healthcare, Fullerton Healthcare Group and ViAqua Therapeutics, where he led teams across Singapore, Hong Kong, South East Asia and Israel. Prior, he spent over a decade in investment banking with Royal Bank of Scotland, specializing in corporate strategy and capital markets coverage.
Eng Seng served on private and public boards, managing investor relations, and multi-disciplinary teams across regional markets, bringing a unique blend of strategic foresight and executional depth to Tamarind Health’s leadership team.
Sachin is a finance leader and Chartered Accountant with over 20 years of experience in driving financial transformation, corporate governance, and strategic growth across leading organizations in Asia and beyond. As Group Chief Financial Officer at Tamarind Health, he oversees the group’s financial strategy, capital management, and operational excellence across multiple markets.
Before joining Tamarind Health, Sachin held Chief Financial Officer roles at Healthway Medical Group, Adcorp Holdings, and Amtek Global Technologies, where he led international finance operations spanning Asia, Australia, and Africa. He also served as Chief Financial Officer at Sembawang Engineers and Constructors, managing group finance, M&A, and IPO readiness.
Sachin has a proven track record in fundraising, restructuring, M&A integration, and strategic planning, with deep expertise in aligning financial performance to long-term business growth. He is recognized for his analytical rigor, execution focus, and collaborative leadership, bringing strong financial stewardship to Tamarind Health’s leadership team.
Bob brings extensive experience across healthcare investment, corporate development, and management consulting, with a career spanning Asia, Australia, and the United States. As Senior Vice President of Operations and Corporate Development at Tamarind Health, he drives strategic initiatives, acquisitions, partnerships, and business transformation across the group’s oncology network.
Before joining Tamarind Health, Bob was Executive Director at Tikehau Capital, where he led healthcare investments and portfolio value creation across the Asia-Pacific region. He previously held a senior investment role at Seidler Equity Australia and also worked at Archer Capital in Sydney.
He began his career as a Consultant at Bain & Company in New York, Shanghai, and Sydney, advising clients on growth strategy and operational excellence.
Bob holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from University of New South Wales and a Master of Business Administration (MBA) from the Wharton School of the University of Pennsylvania, combining clinical insight with financial and operational acumen to advance Tamarind Health’s mission of delivering world-class oncology care across Asia.
Bi Zhen is the Senior Vice President, Business Transformation at Tamarind Health, where she leads clinical and operational excellence initiatives across the Group and drives enterprise-wide transformation efforts.
She brings deep healthcare experience spanning clinical practice, operations, and leadership. Since the inception of Singapore Breast Surgery Center (SBSC), Bi Zhen has been instrumental in shaping the organisation, guiding it through key milestones, and contributing significantly to its growth as General Manager.
Prior to SBSC, she was the Senior Manager at AsiaMedic Limited. She began her career as a Diagnostic Medical Sonographer and Radiographer, and spent over 14 years at National University Hospital, building a strong foundation in patient care and clinical operations.
Bi Zhen holds a Master of Science in Diagnostic Medical Sonography from Monash University.
Cliff serves on the Board of Tamarind Health and is the Founding Partner and Chief Executive Officer of Templewater.
Francis serves on the Board of Tamarind Health and is Managing Director and Chief Corporate Officer at 65 Equity Partners.
Senior Medical Oncologist
MBBS (Singapore), MRCP (United Kingdom),
M.Med (Singapore), FAMS (Medical Oncology),
Palliative Medicine
Clinical Interests: Urological Cancers (Prostate, Kidney, Testicular, Bladder), Brain Tumour, Lung Cancer, Cancers of Liver, Stomach, Colon & Rectum.
Dr Tay Miah Hiang serves on the Board of Tamarind Health. He is a Senior Consultant Medical Oncologist at OncoCare Cancer Centre with over 30 years of clinical experience. Known for his patient-first and compassionate approach, his subspecialty interests include lung, gastrointestinal (stomach, colon, rectum), hepatobiliary, and genitourinary cancers (liver, prostate, kidney, testicular, bladder), as well as brain tumors and gynecological cancers (ovarian, uterine, cervical).
Before joining OncoCare, Dr Tay served as a Consultant at the National Cancer Centre Singapore, where he led Patient Education and Survivorship programmes—championing informed and empowered care. After moving into private practice, he went on to be the elected Chairman of Gleneagles Medical Advisory Board from 2014 to 2016. He was an elected member of the Singapore Medical Council from 2017 to 2023, contributing to healthcare governance and upholding ethical standards. Dr Tay also served on the board of the Children’s Cancer Foundation (CCF) from 2006 to 2015, including a term as Chairperson from 2011 to 2013. He continues to contribute today as an advisor.
Beyond his clinical and governance roles, Dr Tay is deeply committed to education, philanthropy and youth development. Drawing inspiration from his own background as a bursary recipient, he founded the OncoCare Medical Bursary at the NUS Yong Loo Lin School of Medicine to support financially challenged students.
He has also played a significant role in nurturing junior squash talent in Singapore by sponsoring national youth tournaments and creating the “Singapore Next Rising Star” award to inspire young athletes. His commitment to giving back extends to the broader community. He led a fundraising walkathon in support of the Straits Times School Pocket Money Fund, and under his leadership, OncoCare actively participated in the Children’s Cancer Foundation’s Hair for Hope initiative.
Dr Tay’s dedication to medical excellence, community outreach and socially responsible care continues to empower patients, support future generations of healthcare professionals, and uplift underserved communities.
He is fluent in English, Mandarin, Hokkien, Teochew, Malay, and Bahasa Indonesia, enabling him to communicate meaningfully with patients from diverse cultural and linguistic backgrounds.
MEDICAL PROFILE
Dr Ang Peng Tiam
Senior Medical Oncologist
MBBS (Singapore), MRCP (United Kingdom),
M.Med (Singapore), FAMS (Medical Oncology),
FRCP (London), FRCP (Edinburgh), FACP (USA)
Clinical Interests: Lymphoma, Breast Cancer, Lung Cancer, Cancers of Liver, Stomach, Colon & Rectum, Kidney, Bladder and Prostate Cancer.
Dr Ang Peng Tiam serves on the Board of Tamarind Health. He is the Medical Director and Senior Consultant Medical Oncologist at Parkway Cancer Centre, with over 40 years of clinical experience. A well-known leader in the field of cancer care, he has a strong local and regional following of patients from Malaysia, Indonesia, Vietnam, the Philippines, India, Bangladesh, Sri Lanka, and beyond.
Dr Ang was the Founding Head and Senior Consultant in the Department of Medical Oncology, Singapore General Hospital. He held the concurrent appointment of Clinical Associate Professor at National University of Singapore. He was instrumental in establishing Medical Oncology as a speciality in Singapore and training a generation of medical oncologists, many of whom have gone on to leadership positions both in the public and private sector.
Dr Ang was one of the Founder Doctors of Singapore Cancer Centre. The company was listed in the Singapore Exchange as TalkMed in January 2014 and Dr Ang remained the Chief Executive Officer from incorporation until it was delisted in September 2025. He is currently a board member in Tamarind Health, which now wholly owns TalkMed and all its subsidiaries.
Besides his clinical role, Dr Ang was the longest serving council member in Singapore Cancer Society. He was previously the Vice-Chairman of Singapore Cancer Society. He has served in many posts including Chairman pf Public Education and Chairman of the Community Partnership Committee. He was responsible for championing fund raising projects to support the needs of cancer patients. Dr Ang was also a past-President of Singapore Society of Oncology.
Dr Ang was educated in Anglo-Chinese School and has been actively involved in his alumni since 1990. He has served in many posts including President of ACS Old Boy’s Association, Vice-Chairman of the ACS Board of Governors and member of the ACS International Board of Management.
Dr Ang is a believer in Christ and he worships with his family at Barker Road Methodist Church. He is married to Siok Lin and blessed with four children (all of whom are doctors) and seven grandchildren.
Dr Ang has authored more than 100 papers and abstracts in the medical literature and actively participated in many international cancer conferences and forum. He has also authored several books such as Doctor, I Have Cancer. Can Your Help Me? (published in 2006), Stories of Hope (published in 2009) and Hope and Healing (published in 2014). He was contributor to Straits Times – Mind Your Body column.
Dr Ang completed his medical oncology fellowship at MD Anderson Cancer Center in Houston, Texas and Stanford University in Palo Alto, California.
Dr Ang was awarded Singapore’s President Scholarship in 1977. He received the Professor Sir Gordon Arthur Ransome Gold medal for being the top candidate in the Master of Medicine (Internal Medicine) examination in 1986. He was awarded Singapore’s National Science award in 1996.
He was conferred a datukship by the Sultan of Kedah for his public contributions in Medicine in 2003.
Senior Medical Oncologist
MBBS (Singapore), MRCP (United Kingdom),
M.Med (Singapore), FAMS (Medical Oncology),
Palliative Medicine
Clinical Interests: Breast cancer, Breast Cancer Genetics, Young-onset Breast Cancer, Lung Cancer.
Dr Peter Ang serves on the Board of Tamarind Health. He is a Senior Consultant Medical Oncologist at OncoCare Cancer Centre with over 30 years of clinical experience. His areas of expertise include breast cancer, breast cancer genetics, young-onset breast cancer, and lung cancer.
Graduating from the National University of Singapore in 1991, he earned his Master of Medicine (Internal Medicine) and Membership of the Royal College of Physicians (UK) in 1997. In 2000, he received the Ministry of Health HMDP Scholarship to train at Dana Farber Cancer Institute, Boston, USA, focusing on breast cancer and cancer genetics. He also qualified in the European Society of Medical Oncology (ESMO) certifying exam and, in 2001, was among the first to achieve certification in Familial Cancer Risk Assessment and Management.
Before private practice, Dr Ang was Senior Consultant Medical Oncologist and Director of the Cancer Education Service (2004) at the National Cancer Centre Singapore, and visiting consultant to KK Hospital to establish cancer genetics services. As lead of the Breast Cancer Workgroup (2002) for the National Cancer Centre and SingHealth, he helped implement the Breast Cancer Health Management Plan (2003). He also led Public Cancer Education at SingHealth (2004) and received the National Excellent Service Award (EXSA) in 2005. His clinical expertise covers a wide range of cancers, including lung, stomach, colorectal, lymphoma, kidney, ovarian, uterine, and cervical cancers.
He is the author and editor of Illustrative Cases in Breast Cancer (2006), and he has reviewed for leading medical journals. His research includes breast cancer in women under 35, non-small cell lung cancer, irinotecan in colorectal cancer, gemcitabine with pegylated liposomal doxorubicin in metastatic breast cancer, lapatinib for HER2-positive disease, and pharmacogenomic studies in Asian patients.
A recognised authority in breast cancer, he has spoken at the Breast Cancer Foundation, the Singapore Cancer Society, and major oncology conferences, including the Singapore Medical Oncology Review Course (2007), Asian Oncology Summit (2009), and Asia Breast Cancer Collaborative Group Meeting (2010). He has led over 10 clinical trials involving chemotherapy and targeted therapies such as herceptin, lapatinib, and sunitinib.
His work has been published in journals including Journal of Clinical Oncology, Chest, Lancet Oncology, Clinical Cancer Research, and the New England Journal of Medicine.
Fluent in English, Mandarin, and Hokkien, Teochew dialects, Dr Ang also speaks some Malay and Bahasa, and has cared for patients from Indonesia, Vietnam, Russia, Myanmar, and Cambodia.
MEDICAL PROFILE
Simon Chuk serves on the Board of Tamarind Health and is a Partner at Templewater.